Beacon Biosignals Secures $86M Series B Funding to Advance Neurodiagnostic AI

Beacon Biosignals, a pioneer in brain-reading technology, has successfully raised $86 million in an oversubscribed Series B funding round. The company plans to leverage this significant capital injection to develop an extensive neurodiagnostic dataset, furthering its mission to make brain function measurable and actionable at scale.

AI-Driven Biomarkers for Brain Health

At the heart of Beacon Biosignals' innovative approach is the FDA-cleared Waveband system, which measures brain electrical activity during both sleep and wakefulness. This technology, coupled with the Beacon Platform, forms the cornerstone of the company's efforts to advance clinical applications of AI-driven biomarkers for brain health.

The Waveband system collects data across diverse populations, contributing to Beacon's foundation model of brain activity. This model, which already incorporates millions of hours of EEG recordings, aims to detect early disease signatures and potentially predict responses to therapy.

Expanding Clinical Applications

With this new funding, Beacon Biosignals is poised to explore diagnostic pathways for a range of neurological and psychiatric conditions. The company's focus includes:

• Clinical depression
• Parkinson's disease
• Alzheimer's disease
• Sleep apnea

Dr. Jacob Donoghue, co-founder and CEO of Beacon Biosignals, emphasized the company's ambitious goals: "By training AI on millions of hours of real-world brain data, we're beginning to map the signals of health and disease in ways that can accelerate drug development and ultimately improve how patients are diagnosed and treated."

Strategic Growth and Investor Confidence

The oversubscribed Series B round attracted a diverse group of investors, including:

• Innoviva
• Google Ventures (GV)
• Nexus NeuroTech Ventures
• S32
• Catalio Capital Management
• Takeda
• General Catalyst
• Logos Capital
• Casdin Capital
• Indicator Ventures

This latest investment brings Beacon Biosignals' total funding to over $121 million, underscoring strong investor confidence in the company's potential to revolutionize neurodiagnostics.

In a strategic move to enhance its capabilities, Beacon recently acquired CleveMed, a specialist in home sleep testing technology, for an undisclosed sum. This acquisition, completed in April, is expected to complement Beacon's existing portfolio and strengthen its position in the sleep monitoring market.